Drug intelligence / Profile preview

opucolimab

Development stage: Phase 1
Lead developer: Henlius
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Opucolimab (HLX20) is a recombinant human monoclonal antibody of the IgG4 subtype that targets programmed death-ligand 1 (PD-L1). By binding to PD-L1 on tumor cells and immune cells in the tumor microenvironment, it blocks the interaction between PD-L1 and its receptor PD-1 on T cells. This inhibition releases the "brakes" on T cell activation and restores anti-tumor immune responses. Opucolimab is being developed primarily for use in advanced solid tumors as an immuno-oncology therapy. The drug was developed by Henlius (Fosun Pharma)[1][2][3][4][5].

Other names: opucolimabHLX20HLX-20HLX 20

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on opucolimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on opucolimab.

Explore the full profile